Secreted group IIA phospholipase A2 protects humans against the group B streptococcus: Experimental and clinical evidence

Journal of Infectious Diseases

Volumn 208, Issue 12, 2013, Pages 2025-2035

  Movert, Elin ^a   Wu, Yongzheng ^b,c   Lambeau, Gérard ^d   Kahn, Fredrik ^a   Touqui, Lhousseine ^b,c   Areschoug, Thomas ^a  

^a LUND UNIVERSITY   (Sweden)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

^d INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Antimicrobial molecules; Bactericidal; Group B streptococcus; Innate immunity

Indexed keywords

PHOSPHOLIPASE A2 GROUP II; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME RELEASE; FEMALE; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IN VIVO STUDY; INNATE IMMUNITY; LUNG INFECTION; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STREPTOCOCCUS AGALACTIAE; VERY ELDERLY; ACUTE DISEASE; ANIMAL; ANTIMICROBIAL MOLECULES; BACTERICIDAL; BLOOD; ENZYMOLOGY; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LUNG DISEASE; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; STREPTOCOCCUS INFECTION; TRANSGENIC MOUSE;

ANTIMICROBIAL MOLECULES; BACTERICIDAL; GROUP B STREPTOCOCCUS; INNATE IMMUNITY;

ACUTE DISEASE; ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; FEMALE; GROUP II PHOSPHOLIPASES A2; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFANT, NEWBORN; LUNG DISEASES; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84897118527     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit359     Document Type: Article

References (47)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-95.
2. Areschoug T, Pluddemann A, Gordon S. Innate immunity against bacteria. In: Kaufmann SHE, Rouse B, Sacks D, eds. Immune response to infection. 2nd ed. Washington, DC: ASM Press, 2011:209-223.
3. 2. Review. Biochim Biophys Acta 2008; 1781:1-9.
4. Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL- 37 in mucosal immunity. J Leukoc Biol 2010; 87:79-92.
5. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012; 379:547-56.
6. Lindahl G, Mhammar-Carlemalm M, Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev 2005; 18:102-27.
7. Doran KS, Nizet V. Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy. Mol Microbiol 2004; 54: 23-31.
8. Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis 2005; 41:839-47.
9. Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009; 49:85-92.
10. 2: role of Streptococcus pyogenes Sortase A. J Immunol 2011; 187: 6437-46.
11. 2. Trends Biochem Sci 2010; 35:28-35.
12. 2 is an endogenous antibiotic-like protein of the host. Biochimie 2010;92:583-7.
13. 2. Annu Rev Biochem 2008; 77:495-520.
14. 2 against Staphylococcus aureus. J Immunol 1999; 162:7402-8.
15. 2: A major physiological role for the group IIA enzyme that depends on the very high pi of the enzyme to allow penetration of the bacterial cell wall. J Biol Chem 2002; 277:1788-93.
16. 2 against Bacillus anthracis and inhibition of its secretion by the lethal toxin. J Immunol 2004; 173:521-30.
17. 2. J Immunol 2001; 166:4029-34.
18. 2. J Clin Invest 1995;95:603-10.
19. 2. J Clin Invest 1996; 97:250-7.
20. 2. J Biol Chem 2002; 277:5849-57.
21. 2 lacking hydrolytic activity retain their bactericidal effect. Biochimie 2012; 94:132-6.
22. 2 synthesis. J Immunol 1997; 159:391-400.
23. 2 in serum of patients with bacterial infections. J Infect Dis 2002; 185:1767-72.
24. Lancefield RC, McCarty M, Everly WN. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med 1975; 142:165-79.
25. Stilhammar-Carlemalm M, Stenberg L, Lindahl G. Protein Rib: A novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med 1993; 177:1593-603.
26. Barnett TC, Scott JR. Differential recognition of surface proteins in Streptococcus pyogenes by two sortase gene homologs. J Bacteriol 2002; 184:2181-91.
27. 2 are natural ligands of the mouse 180- kDa M-type receptor. J Biol Chem 1999; 274:7043-51.
28. 2. J Biol Chem 2002; 277: 48535-49.
29. 2 at 1.5 A resolution provides an insight into the catalytic mechanism. Biochemistry 2002; 41:15468-76.
30. 2 in human serum. Biochim Biophys Acta 2005; 1733:210-23.
31. 2 in animal models of acute lung injury. Eur Respir J 2003; 21:1040-5.
32. 2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J Clin Invest 1996; 97:2233-41.
33. 2 gene in inbred mouse strains. J Biol Chem 1995; 270:22378-85.
34. Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol 2009; 16: 41-7.
35. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A 1995;92:11490-4.
36. Butko P, Nicholson-Weller A, Wessels MR. Role of complement component Clq in the IgG-independent opsonophagocytosis of group B streptococcus. J Immunol 1999; 163:2761-8.
37. Mancuso G, Gambuzza M, Midiri A, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009; 10:587-94.
38. Henneke P, Dramsi S, Mancuso G, et al. Lipoproteins are critical TLR2 activating toxins in group B streptococcal sepsis. J Immunol 2008; 180: 6149-58.
39. Dorschner RA, Lin KH, Murakami M, Gallo RL. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res 2003; 53:566-72.
40. 2 by guinea pig alveolar macrophages. Dissociation from arachidonic acid liberation and modulation by dexamethasone. J Immunol 1993; 151:5613-23.
41. 2 expression in alveolar macrophages. FEBS Lett 2005; 579:4923-7.
42. 2-a in arachidonic acid release and platelet activating factor synthesis. Biochim Biophys Acta 2009; 1791:92-102.
43. 2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005; 33:772-9.
44. 2 and their modulators in meconium aspiration syndrome in human neonates. Intensive Care Med 2011; 37:1158-65.
45. 2: A marker of infection in febrile children presenting to a pediatric ED. Am J Emerg Med 2011; 29: 1163-8.
46. 2 against Staphylococcus aureus. J Biol Chem 2002; 277:47636-44.
47. 2 expression by alveolar macrophages. PLoS Pathog 2007; 3:e187.